Emergent BioSolutions (EBS) Research & Development (2011 - 2026)
Emergent BioSolutions (EBS) posted Research & Development of $9.2 million for Q2 2026, down 26.4% from $12.5 million a year earlier and down 12.4% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Research & Development (2011 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Emergent BioSolutions was $45.3 million, down 10.3% year-over-year; for FY2025, it was $53.2 million, down 24.8% from FY2024.
- Annual Research & Development has declined for five consecutive years, with a five-year compound annual growth rate of -25.9% (FY2020 to FY2025).
- In prior years, Emergent BioSolutions' Research & Development was $70.7 million in FY2024 (-36.5%), $111.4 million in FY2023 (-40.8%), $188.3 million in FY2022 (-19.9%) and $235.2 million in FY2021 (-1.1%).
- The Q2 2026 figure stands as the lowest quarterly Research & Development since Q4 2024.
- On a year-over-year basis, Research & Development increased in 1 of the last eight quarters, with an average decline of 20.8%.
- The strongest year-over-year quarter for Research & Development in the past five years was Q4 2021, with growth of 33.9%; the weakest was Q4 2024, with a decline of 69.0%.
- According to Business Quant data, Research & Development for the three prior quarters was $10.5 million (Q1 2026), $12.1 million (Q4 2025) and $13.5 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,152.93 Bn | 1,121.51 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 623.85 Bn | 542.38 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 512.32 Bn | 485.43 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 365.51 Bn | 319.89 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.25 Bn | 261.24 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.29 Bn | 234.98 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 234.60 Bn | 190.00 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 192.87 Bn | 167.07 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.71 Bn | 118.36 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Emergent BioSolutions | 318.89 Mn | -432.01 Mn | 137.20 Mn | 9.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 12.10 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 9.10 Mn |
| Sep 30, 2024 | 13.80 Mn |
| Jun 30, 2024 | 32.70 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 29.40 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 26.00 Mn |
| Mar 31, 2023 | 40.70 Mn |
| Dec 31, 2022 | 47.00 Mn |
| Sep 30, 2022 | 42.20 Mn |
| Jun 30, 2022 | 49.80 Mn |
| Mar 31, 2022 | 46.40 Mn |
| Dec 31, 2021 | 84.20 Mn |
| Sep 30, 2021 | 49.60 Mn |
API Access
Emergent BioSolutions Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();